🔗 Share this article

As the US undertakes historic revisions to its vaccine recommendations, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on Covid vaccines during the pandemic and has concentrated on possible deaths following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Public health authorities were set to announce major revisions to the pediatric vaccination calendar in December, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US at odds with a large portion of the global community with insufficient data for improved outcomes. The announcement has been delayed until the new year.

In place of Vinay Prasad, Dr. Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to lead the division this year.

A Shift at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood shot schedules in the US to become more like the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Qualifications

Dr. Høeg has no apparent track record in medication creation, approval processes or leadership, which has been customary for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She has no expertise in drug approvals.”

Previous commissioners of CBER would “understand laws and regulations and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led CBER have had.”

The drug center has an immense portfolio at the agency, the former commissioner stated.

“Many people just focuses on the innovative therapies, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and other areas, and all of those must be managed,” Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant leadership element to the job, which oversees over 5,000 personnel. “It’s a massive management job, if you do it right,” she concluded.

Official Statement and Disputed Policies

In response to inquiries about Høeg’s qualifications and whether this appointment represents increased cooperation among agency officials on immunizations, a press secretary stated that the “inquiries rely on inaccurate assumptions”.

“This background matches the responsibilities of her role,” the official stated, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed rapid therapy clearance system that reportedly worried her former heads. “By what process are these drugs being picked for this expedited pathway? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent regulations of all drugs, with the exception of vaccines.”

Public History on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, history, some experts have noted. She authored a study using unverified crowd-sourced reports to determine the rate of heart inflammation following COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the new government encompassed changing regulations for recently developed shots and discontinuing “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources suggested preventing adolescent males from getting Covid vaccinations.

“She is an complete ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the science in a extremely misleading, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|